The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Sep. 4, 6:20 AM

Slide #6. MediciNova, Inc. Secondary Offering

Company: MediciNova, Inc. (NASDAQ:MNOV)
Date announced: 8/18/2015
Shares Offered: 5,000,000
Date of Pricing: 8/18/2015
Price Per Share: $3.50
Secondary Offering Details: MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by MediciNova. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 8/18 - MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $3.50 per share. The gross proceeds to MediciNova from this offering are expected to be $17.5 million, before deducting the underwriting discount and other estimated offering expenses. All of the shares of common stock to be sold in the offering are being offered by MediciNova. In addition, MediciNova has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock. The offering is expected to close on or about August 24, 2015, subject to customary closing conditions.

Medicinova is a biopharmaceutical company focused on developing small molecule therapeutics for the treatment of diseases. Co. focuses its development activities on MN-166 (Ibudilast) for the treatment of neurological disorders, MN-221 (Bedoradrine) for the treatment of acute exacerbations of asthma, MN-001 (Tipelukast) for the treatment of nonalcoholic steatohepatitis (NASH), and MN-029 (Denibulin) for the treatment of solid tumors. Co. has licenses to MN-166, MN-221, MN-001, and MN-029 for the development of four product candidates including clinical development for the treatment of progressive multiple sclerosis, addictions, acute exacerbations of asthma, NASH, and solid tumor cancers.
Open the MNOV Page at The Online Investor »

Company Name:  Medicinova Inc
Website:  www.medicinova.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding MNOV:  1
Total Market Value Held by ETFs:  $193635
Total Market Capitalization:  $76.00M
% of Market Cap. Held by ETFs:  0.25%
 

Open the MNOV Page at The Online Investor (in a new window) »

September 4, 2015    6:20 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
89th percentile
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.